Shining3D Tech Co., Ltd. Sued for Infringement; Qinghai and Tibet Plan to Integrate Dental Service Pricing; Align Technology Patent Litigation Ruling: Infringement Established but Patent Invalid; Man…

Shining3D Tech Co., Ltd. Sued for Patent Infringement, SprintRay Formally Files Lawsuit

On June 18, 2026, SprintRay, Inc. (a California-based company) filed a lawsuit in the U.S. District Court for the Central District of California against Shining3D Tech Co., Ltd. and its U.S. affiliates, alleging that their AccuFab-F1 and AccuFab-CEL dental 3D printers infringe five U.S. patents related to key technologies such as resin curing, reservoir structure, and printing separation force. The case has been accepted under case number 4:26-cv-06026 and is currently in the early stages of litigation.

Qinghai Proposes to Integrate Dental Service Pricing, Sets Price Ceiling for Full-Mouth Scaling at 392 Yuan

On June 24, 2026, the Qinghai Provincial Healthcare Security Administration published a notice proposing adjustments to dental medical service pricing items, along with a special project guidance document. Among the proposed prices, the guidance price for orthodontic treatment during the deciduous dentition period at tertiary hospitals is set at 3,000 yuan per course of treatment, while full-mouth scaling, polishing, and air polishing combined total 392 yuan. The maximum price for the extraction of a fully impacted wisdom tooth is 400 yuan per tooth, with no separate design fees allowed, and no cumulative surcharges for complex cases. According to previous reports by DENTALGOODNEWS (Leading Dental Industry Media, DGN), several provinces including Henan, Chongqing, and Ningxia have recently been advancing the standardization and integration of dental service pricing.

Tibet Standardizes 195 Dental Service Pricing Items, Fully Impacted Wisdom Tooth Extraction Capped at 354 Yuan per Tooth

The Tibet Autonomous Region Healthcare Security Administration issued a notice standardizing dental medical service pricing items into 195 categories, while discontinuing 201 original service items. All published service prices are price ceilings. Among them, impacted tooth extraction is priced at 200 yuan per tooth, with an additional 154 yuan per tooth for complex impacted teeth. For a fully impacted wisdom tooth at a tertiary hospital, the maximum extraction fee is 354 yuan (excluding anesthesia, examination, imaging, and medication costs). Additionally, designated medical institutions at all levels are required to display prices prominently and accept public supervision.

Align Technology Patent Verdict: ClearCorrect Found Infringing but Patents Invalidated, No Damages Awarded in This Round

On July 2, 2026, a federal jury in the Western District of Texas ruled that ClearCorrect's ClearQuartz clear aligners infringe multiple patents held by Align Technology, Inc. However, the jury also found all of these patents invalid, thus awarding no damages. The jury also ruled in favor of Align Technology on ClearCorrect's antitrust counterclaims. As of press time, neither Align Technology nor Straumann has issued further statements regarding this verdict.

Mani Establishes First Production Base in China in Foshan, Localized Production Shortens Product Registration Cycle

Recently, Mani Co., Ltd. signed an agreement for its first production base in Nanhai, Foshan, with a total investment of approximately 1.2 billion yen. The first phase will produce high-end ophthalmic surgical knives, while the second phase will focus on dental instruments. The localization is expected to shorten the product registration cycle from approximately 18 months to about 9 months. According to the Foshan Municipal Health Bureau, the project is surrounded by over 300 dental instrument companies, with dental chairs and dental handpieces holding market shares exceeding 70% and 90%, respectively. The bureau also stated that Nanhai District will continue to support foreign-invested enterprises in expanding production and enhancing the technological level of the industrial chain.

Jiahong Dental Completes BSE Listing Guidance Acceptance

On July 2, 2026, Jiahong Dental received a completion letter from the Shenzhen Securities Regulatory Bureau for its listing guidance on the Beijing Stock Exchange (BSE), under the tutelage of Guosen Securities. The company's net profits for 2024 and 2025 were 51.5045 million yuan and 45.1263 million yuan, respectively, with weighted ROEs of 9.79% and 8.03%, meeting the BSE's financial criteria. The company's main manufacturing bases are located in Shenzhen and Zhuhai. It still faces the risk of failing to pass the BSE issuance and listing review or registration with the China Securities Regulatory Commission.

Lone Peak, One of the Largest Pediatric Dental DSOs in the U.S., Completes $170 Million Refinancing

On July 7, 2026 (EDT), Lone Peak Dental Group, one of the largest pediatric dental DSOs in the U.S., completed a $170 million (approximately 1.155 billion yuan) refinancing. TCW Steel City served as the lead arranger, with Brightwood, CIFC, and CalSTRS participating. The financing includes a term loan, a revolving credit facility, and a delayed draw term loan, aimed at supporting its acquisition expansion across approximately 75 locations in 14 states. In June, the company had secured $15 million in mezzanine debt from o15 Capital Partners. TCW Steel City is a private credit platform created through a partnership between TCW Group and PNC Bank, focusing on middle-market direct lending.

South Korean Digital Dental Technology Company Innovaid Secures 12 Billion Won in Funding

Recently, Innovaid, a South Korean digital denture platform, completed a Series B funding round of approximately 12 billion won (about $8.8 million), led by SBVA. The company claims its AI technology reduces the denture remake rate to 0.6% and will use the funds to build a robot-linked automated manufacturing center and expand into markets such as the U.S. and Australia. Its revenue grew from 3.7 billion won in 2024 to 8.2 billion won in 2025, with a target of 20 billion won in revenue for 2026. The centers in South Korea and Australia are expected to be completed in the second half of 2026. The company has not yet disclosed its post-funding valuation or changes in shareholding ratio.

South Korean Implant Company DIO Partners with IT Service Company LG CNS to Build AI-Automated Implant Surgery Design Platform

On June 30, 2026, South Korea's DIO Company signed a memorandum of understanding with LG CNS in Seoul to jointly build an AI-powered oral implant surgery design and cloud platform covering over 70 countries, aiming to shorten design time and ensure data security. DIO reported 2025 revenue of 164.1 billion won, a 37% year-over-year increase, with 83% growth in the Chinese market. The company has initiated a dual-axis production system in Ziyang, Sichuan, with an annual capacity of 750,000 units, planning to expand to 3 million units. As of press time, the parties have not disclosed the specific launch date for the AI platform.

Lepu Medical's Controlling Shareholder Pledges 27.93 Million Shares for Debt Repayment, Cumulative Pledge Ratio Rises to 39.87%

On July 2, 2026, Pu Zhongjie, the controlling shareholder of Lepu Medical, pledged an additional 27.93 million shares (6.13% of his holdings) and subsequently released 11.93 million shares from pledge the following day. The cumulative pledged shares amount to 181.67 million, representing 9.86% of the company's total share capital and 39.87% of his personal holdings. The company stated that the pledges have not triggered margin calls and do not affect actual control.

Align Technology's Invisalign VAT Exemption Claim Dismissed, UK Court Rules Clear Aligners Are Not Dental Prostheses

On July 7, 2026, the Tax and Chancery Chamber of the Upper Tribunal in the UK ruled that Invisalign clear aligners do not qualify for the dental prosthesis exemption under the Value Added Tax Act 1994 and must be subject to the standard VAT rate. This ruling overturned a lower court decision in favor of Align Technology. Subsequently, on June 30, 2026, the European Commission launched its first antitrust investigation into Align Technology in the medical device sector, focusing on its bundling of Invisalign with iTero scanners and restrictions on interoperability.

Average Debt of U.S. Dental Students Nears $300,000, Growing Approximately 5.9 Times After Inflation Over 30 Years

A recent report by Education Data Initiative shows that the average debt for U.S. dental graduates in 2025 is approximately $297,800, with an average dental school debt of $280,300, about 140% of the federal loan limit. Approximately 79% of graduates finance their tuition through loans, covering about 65% of costs. Since 1996, inflation-adjusted debt has grown by approximately 588%. The report also notes that for the 2024-25 academic year, the first-year cost for in-state students at public schools is about $46,900, while private school first-year costs average $87,100. The University of Puerto Rico has the lowest total cost at $118,900, while the Ostrow School of Dentistry at the University of Southern California has the highest at $492,800.

BDA Criticizes NHS Mandatory Bonding Policy as a "Straitjacket" for the Profession, Potentially Exacerbating Talent Drain

On July 2, 2026, the British Dental Association (BDA) warned against a government-proposed policy requiring dental graduates to provide a certain proportion of NHS dental services for a specified period, with potential penalties for non-compliance. The association called the policy a "straitjacket" for the profession, stating it would undermine the attractiveness of an NHS dental career and worsen the talent drain. The BDA revealed that current students would be exempt, and the obligation would only constitute part of the weekly working hours. The association will continue to engage with the government to seek more favorable policy outcomes.

New Research on Enamel Regeneration: Notch-Activated Ameloblast Organoids Achieve In Vivo Enamel-Like Mineralization for the First Time

Recently, the "International Journal of Oral Science" reported that a research team treated hiPSC-derived ameloblast organoids with a soluble artificial Notch agonist, C3-DLL4, leading to high expression of maturation markers and the formation of enamel-like calcified deposits under the renal capsule of immunodeficient NOD-SCID mice. This is the first confirmation that Notch activation can induce enamel-like tissue in vivo. The study also indicated that DLX3 plays a cell-autonomous regulatory role in the terminal maturation of human ameloblasts. This experiment remains at the animal stage, and the conclusions are not yet directly translatable to clinical application.